Alnylam Highlights Zilebesiran for Hypertension, but Near-Term Focus Remains AMVUTTRA

What happened

Alnylam held an RNAi Roundtable to detail zilebesiran, an investigational RNAi therapy for twice-yearly blood pressure control in high-risk hypertension patients, emphasizing the large unmet need due to poor adherence to daily pills. This development aligns with Alnylam's broader strategy (Alnylam P x25) to extend RNAi beyond rare diseases into prevalent conditions, as exemplified by Leqvio. However, the company's near-term value remains dominated by AMVUTTRA in ATTR-CM, where it faces intense competition from BridgeBio's Attruby and regulatory scrutiny, with the stock trading at $331 and no margin of safety per the DeepValue report. The zilebesiran news does not alter the immediate revenue trajectory or the FY2026 combined net product revenue guidance of $4.9B–$5.3B, but it adds pipeline optionality that could support long-term growth if clinical trials succeed. Consequently, the master report's WAIT rating and attractive entry at $300 remain unchanged by this development.

Implication

Investors should view the zilebesiran news as a reminder of Alnylam's long-term RNAi platform potential in large cardiovascular markets, but it remains early-stage and does not impact near-term financials. The core investment case still hinges on AMVUTTRA's ability to meet FY2026 revenue guidance of $4.9B–$5.3B amidst competition from BridgeBio's Attruby and payer scrutiny. Given the stock's recent volatility and the lack of margin of safety at $331, the prudent approach is to wait for either a pullback to the $300 entry level or confirmation of sustained AMVUTTRA growth. The subpoena-related overhang and potential gross-to-net adjustments add asymmetric downside risk that this pipeline update cannot offset. Therefore, we maintain a WAIT rating and advise investors to monitor quarterly AMVUTTRA sales, payer policy changes, and compliance developments before adding positions.

Thesis delta

The zilebesiran update introduces additional long-term optionality in hypertension, but it does not alter our near-term thesis. Our investment stance remains unchanged: ALNY is a WAIT at current levels, with AMVUTTRA execution and compliance risks dominating the next 6-9 months. We see no need to adjust our valuation or entry levels based on this development.